Treatment Protocols for Patients with Symptomatic Low-risk MDS

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: December 09, 2020
Expiration Date: December 09, 2021

Expected time to complete this activity as designed: 30 minutes

There are no fees for participating in or receiving credit for this online activity.

Program Overview

In this activity, Dr. Rami Komrokji explains how to manage patients with lower-risk MDS. He will take you through diagnosis, risk stratification, and tailoring treatment. He will also cover patients with genetic mutations, ring sideroblasts, and cytopenias.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Summarize current standards of care for patients with signs of anemia and severe thrombocytopenia
  • Describe the recently approved agent for use in lower-risk MDS RS or MDS RST and where this approach fits in the treatment algorithm
  • Evaluate emerging data from clinical trials on therapy-related regimens for low-risk MDS being explored for their potential role in treatment


Treatment Protocols for Patients with Symptomatic Low-risk MDS – Rami S. Komrokji, MD

Instructions for Participation and Credit

This activity is eligible for credit through December 09, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Rami S. Komrokji, MD
Professor of Medicine and Oncologic Sciences
University of South Florida College of Medicine
Vice Chair, Malignant Hematology Department
Moffitt Cancer Center
Tampa, Florida

Dr. Rami Komrokji received his medical degree from Jordan University School of Medicine. He completed an internship and residency at Case Western University, St. Vincent Program. He then completed a fellowship at Strong Memorial Hospital, University of Rochester in hematology/oncology and hematopoietic stem cell transplantation. Dr. Komrokji is Professor of Medicine & Oncologic Sciences (MOS) at the College of Medicine at the University of South Florida in Tampa, Vice Chair of the Malignant Hematology Department, and the head of the Leukemia and MDS Section at the Moffitt Cancer Center, Tampa. In addition, he is a senior member of the Malignant Hematology and Experimental Therapeutics Program at the Moffitt Cancer Center.

Dr. Komrokji has authored or co-authored more than 200 peer-reviewed manuscripts, 20 book chapters, and more than 300 abstracts in hematologic malignancies. He serves as member on the myelodysplastic syndromes (MDS) panel of the National Comprehensive Cancer Network (NCCN). He was a member of the editorial board for the Journal of Clinical Oncology and is peer reviewer for several medical journals including Blood, Journal of Clinical Oncology, and Leukemia.

Dr. Komrokji’s interests are in phase I and II clinical trials, and in outcomes research in hematologic malignancies with a focus on myeloid neoplasms. His clinical interests are MDS, acute leukemias, and myeloproliferative neoplasms.


MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-20-041-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.


AAs an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Rami Komrokji has received honoraria as a consultant from AbbVie Inc., Acceleron Pharma, Agios, Bristol-Myers Squibb Company, Celgene Corporation – A Bristol-Myers Squibb Company, Geron, Incyte Corporation, Jazz Pharmaceuticals plc, Novartis AG, and Pfizer Inc., as well as speakers’ bureau activities from AbbVie, Agios, Bristol-Myers Squibb, Celgene, and Jazz.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Wilma Guerra, Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.